Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agreement to be acquired by Novartis.

Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim ...

Permeasis Therapeutics (“Permeasis”), a biotechnology company developing intracellular biologics enabled by its proprietary Membrane Translocation Domain (MTD) platform announced the publication of ...

INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...